175 related articles for article (PubMed ID: 2846576)
21. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
[TBL] [Abstract][Full Text] [Related]
22. A carboline derivative as a novel mammalian DNA topoisomerase II targeting agent.
Pognan F; Saucier JM; Paoletti C; Kaczmarek L; Nantka-Namirski P; Mordarski M; Peczynska-Czoch W
Biochem Pharmacol; 1992 Dec; 44(11):2149-55. PubMed ID: 1335251
[TBL] [Abstract][Full Text] [Related]
23. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
Lelièvre S; Benchokroun Y; Larsen AK
Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
[TBL] [Abstract][Full Text] [Related]
24. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
[TBL] [Abstract][Full Text] [Related]
25. Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells.
Jensen LH; Dejligbjerg M; Hansen LT; Grauslund M; Jensen PB; Sehested M
BMC Pharmacol; 2004 Dec; 4():31. PubMed ID: 15575955
[TBL] [Abstract][Full Text] [Related]
26. Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei.
Pommier Y; Schwartz RE; Zwelling LA; Kohn KW
Biochemistry; 1985 Nov; 24(23):6406-10. PubMed ID: 3002439
[TBL] [Abstract][Full Text] [Related]
27. Reduced topoisomerase II and elevated alpha class glutathione S-transferase expression in a multidrug resistant CHO cell line highly cross-resistant to mitomycin C.
Hoban PR; Robson CN; Davies SM; Hall AG; Cattan AR; Hickson ID; Harris AL
Biochem Pharmacol; 1992 Feb; 43(4):685-93. PubMed ID: 1311588
[TBL] [Abstract][Full Text] [Related]
28. Topoisomerase II-dependent and -independent mechanisms of etoposide resistance in Chinese hamster cell lines.
Spiridonidis CA; Chatterjee S; Petzold SJ; Berger NA
Cancer Res; 1989 Feb; 49(3):644-50. PubMed ID: 2535964
[TBL] [Abstract][Full Text] [Related]
29. Topoisomerase II mediated DNA lesions induced by acridine-4-carboxamide and 2-(4-pyridyl)quinoline-8-carboxamide.
Woynarowski JM; McCarthy K; Reynolds B; Beerman TA; Denny WA
Anticancer Drug Des; 1994 Feb; 9(1):9-24. PubMed ID: 8141968
[TBL] [Abstract][Full Text] [Related]
30. DNA double-strand break repair pathways and cellular tolerance to inhibitors of topoisomerase II.
Caldecott K; Banks G; Jeggo P
Cancer Res; 1990 Sep; 50(18):5778-83. PubMed ID: 2168280
[TBL] [Abstract][Full Text] [Related]
31. Reduced formation of protein-associated DNA strand breaks in Chinese hamster cells resistant to topoisomerase II inhibitors.
Pommier Y; Schwartz RE; Zwelling LA; Kerrigan D; Mattern MR; Charcosset JY; Jacquemin-Sablon A; Kohn KW
Cancer Res; 1986 Feb; 46(2):611-6. PubMed ID: 3000581
[TBL] [Abstract][Full Text] [Related]
32. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells.
Holm C; Covey JM; Kerrigan D; Pommier Y
Cancer Res; 1989 Nov; 49(22):6365-8. PubMed ID: 2553254
[TBL] [Abstract][Full Text] [Related]
33. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors.
Pommier Y; Kerrigan D; Schwartz RE; Swack JA; McCurdy A
Cancer Res; 1986 Jun; 46(6):3075-81. PubMed ID: 3009009
[TBL] [Abstract][Full Text] [Related]
34. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
[TBL] [Abstract][Full Text] [Related]
35. Topoisomerase II-mediated DNA damage produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide and related acridines in L1210 cells and isolated nuclei: relation to cytotoxicity.
Covey JM; Kohn KW; Kerrigan D; Tilchen EJ; Pommier Y
Cancer Res; 1988 Feb; 48(4):860-5. PubMed ID: 2827887
[TBL] [Abstract][Full Text] [Related]
36. Mediation of multi-drug resistance in a Chinese hamster ovary cell line by a mutant type II topoisomerase.
Glisson BS; Sullivan DM; Gupta R; Ross WE
NCI Monogr; 1987; (4):89-93. PubMed ID: 2819738
[TBL] [Abstract][Full Text] [Related]
37. Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II.
Nitiss JL; Liu YX; Harbury P; Jannatipour M; Wasserman R; Wang JC
Cancer Res; 1992 Aug; 52(16):4467-72. PubMed ID: 1322791
[TBL] [Abstract][Full Text] [Related]
38. A mutation in yeast topoisomerase II that confers hypersensitivity to multiple classes of topoisomerase II poisons.
Dong J; Walker J; Nitiss JL
J Biol Chem; 2000 Mar; 275(11):7980-7. PubMed ID: 10713116
[TBL] [Abstract][Full Text] [Related]
39. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines.
Fry AM; Chresta CM; Davies SM; Walker MC; Harris AL; Hartley JA; Masters JR; Hickson ID
Cancer Res; 1991 Dec; 51(24):6592-5. PubMed ID: 1660343
[TBL] [Abstract][Full Text] [Related]
40. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
